Author + information
- Andrew P. Ambrosya,b,
- Abhinav Sharmaa,b,
- Steven McNultya,b,
- Barry Borlauga,b,
- Thomas Cappolaa,b,
- Lauren Coopera,b,
- Adam DeVorea,b,
- Shannon Dunlaya,b,
- Anu Lala-Trindadea,b,
- Kenneth Marguliesa,b,
- Robert Mentza,b and
- Eric Velazqueza,b
Background: More than 50% of patients with heart failure (HF) and a reduced ejection fraction (EF) are overweight. Although liraglutide is FDA-approved for weight loss, prior clinical trials excluded patients with HF.
Methods: Patients with a recent hospitalization for HF and an EF <40% were randomized 1:1 to daily subcutaneous liraglutide, a glucagon-like peptide 1 agonist, or matching placebo. An on-treatment analysis was performed of weight loss from baseline to the last completed study visit (i.e. day 30, 90, or 180).
Results: A total of 247 patients (82%) completed at least one study visit while on assigned therapy. Patients were 59+13 years of age, 79% were male, and 58% reported a history of diabetes. Patients randomized to liraglutide experienced greater absolute (Treatment Difference: −4.1 lbs, 95% Confidence Interval [CI] −7.9 lbs, −0.3 lbs; p = 0.04) and relative (-2.1%, 95% CI −3.9%, −0.3%; p = 0.02) weight loss. These findings remained significant after adjusting for NT-proBNP and signs and symptoms of HF (p = 0.03). Liraglutide led to a greater improvement in HgbA1c (-0.5%, p-value = 0.03) and triglycerides (-33 mg/dL, p= 0.02). The incidence of hypoglycemia (liraglutide: 5% vs. placebo: 6%; p = 0.59) and any serious adverse events (liraglutide: 17% vs. placebo: 21%; p = 0.43) did not differ by treatment group.
Conclusions: Liraglutide facilitated greater short-term weight loss and led to favorable improvements in metabolic profile among patients with a recent hospitalization for HF and a reduced EF.
Moderated Poster Contributions
Heart Failure and Cardiomyopathies Moderated Poster Theater, Poster Hall, Hall C
Saturday, March 18, 2017, 10:15 a.m.-10:25 a.m.
Session Title: The Old and the New: Impact of Heart Failure Drug Therapies
Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy
Presentation Number: 1216M-07
- 2017 American College of Cardiology Foundation